Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies

Cellular and Molecular Life Sciences, Journal Year: 2025, Volume and Issue: 82(1)

Published: Jan. 21, 2025

The current opioid crisis has had an unprecedented public health impact. Approved medications for use disorder (OUD) exist, yet their limitations indicate a need innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most evidence remains observational, with few controlled trials. This review aims to bridge the gap between preclinical findings and potential applications, following PRISMA-ScR guidelines. Searches included MEDLINE, Embase, Scopus, Web of Science, focusing on in vivo involving opioids animals, excluding pain those lacking control groups. Forty met criteria, covering both classic non-classic psychedelics. Most showed that 18-methoxycoronaridine (18-MC), ibogaine, noribogaine, ketamine could reduce self-administration, alleviate withdrawal symptoms, change conditioned place preference. However, seven (two 2,5-dimethoxy-4-methylamphetamine (DOM), three one 18-MC, ketamine) no improvement over controls. A methodological quality assessment rated as having unclear quality. Interestingly, are limited iboga derivatives, which were effective, but these agents may have higher cardiovascular risk than other under-explored date. strengthens support translational testing targets OUD. It also suggests include broader range beyond derivatives can explore several ongoing questions field, such mechanism action behind therapeutic effect, safety profiles, doses, frequency administrations needed.

Language: Английский

Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats

Brain, Journal Year: 2024, Volume and Issue: 147(11), P. 3780 - 3788

Published: April 30, 2024

Abstract The use of psilocybin to treat alcohol disorder is very promising, but its mechanisms action remain poorly understood. We combined behavioural, pharmacological and gene expression analyses decipher the psilocybin, for first time, when injected into brain. Male Long Evans rats underwent chronic operant ethanol self-administration before testing effect intraperitoneal or directly within nucleus accumbens core ventral tegmental area. Transcripts from dopaminergic system were quantified in prefrontal cortex. Psilocybin significantly reduced (by 50%) 4 h session either intraperitoneally (1 mg/kg) left (0.15 μg) not right injection was prevented by intra-left 0.3 μg 5-HT2A receptor antagonist ketanserin. In that self-administered those self-administering saccharin, dopamine D2 (D2R) mRNA increased both cortex while D1 only As humans, through accumbens, possibly D2R expression. Our results open unexpected perspectives regarding hemispheric lateralization psychedelic effects.

Language: Английский

Ayahuasca for the treatment of alcohol use disorder

International review of neurobiology, Journal Year: 2024, Volume and Issue: unknown, P. 283 - 300

Published: Jan. 1, 2024

Language: Английский